
- Pontificia Universidad Católica de Chile
- De Francia
- Receptivo
- Investigadores y expertos
Resumen
Especialista en la vinculación de subtipos moleculares del cáncer colorrectal y la heterogeneidad de vesículas extracelulares. Con experiencia en desarrollo de modelos de resistencia al cáncer y análisis de factores de riesgo. Sus investigaciones ofrecen valiosos insights para la industria farmacéutica y de salud.
Proyectos adjudicados
- CONNECTING MOLECULAR SUBTYPES OF COLORECTAL CANCER WITH EXTRACELLULAR VESICLES HETEROGENEITY IN PATIENT-DERIVED ORGANOIDS (2020) Fuente: CONICYT | Rol:
- ESCALON (2019) Fuente: CORDIS | Rol:
- EULAT ERADICATE GBC (2019) Fuente: CORDIS | Rol:
- CIRCULATING EXODNA AS A NEXT GENERATION BIOSPECIMEN FOR LIQUID BIOPSY OF PANCREATICBILIARY CANCERS (2017) Fuente: FONDECYT (1170893) | Rol: COINVESTIGADOR(A)
- PLATFORM OF THERAPY RESPONSE PREDICTION AND DRUG SCREENING USING GALLBLADDER CANCER PATIENTSDERIVED ORGANOIDS (2017) Fuente: FONDECYT (1171463) | Rol: COINVESTIGADOR(A)
- PROTEOMIC SIGNATURE OF GALLBLADDER CANCER SECRETED EXOSOMES=> A DYNAMIC APPROACH TO DELINEATE THEIR POTENTIAL ROLE DURING MALIGNANT PROGRESSION AND THEIR CLINICAL RELEVANCE AS NOVEL RESERVOIR OF CIRCULATING BIOMARKERS. (2015) Fuente: FONDECYT (1151008) | Rol: COINVESTIGADOR(A)
- IDENTIFICATION AND VALIDATION OF EARLY DIAGNOSTIC GALLBLADDER CANCER BIOMARKERS IN CHILEAN PATIENTS BY QUANTITATIVE PROTEOMICS. A PHASE 1 AND 2 BIOMARKER VALIDATION TRIAL. (2013) Fuente: FONDECYT (1130204) | Rol: COINVESTIGADOR(A)
- IDENTIFICATION OF ACTIVATED TYROSINE KINASE SIGNALING PATHWAYD ASSOCIATED WITH DRUG-RESISTANT PHENOTYPE OF GALLBLADDER CANCER BY SILAC-BASED QUANTITATIVE PHOSPHOPROTEOMICS (2013) Fuente: FONDECYT (11130515) | Rol: INV. RESPONSABLE
- EXPRESSION AND BIOLOGICAL FUNCTION OF MIRNA CLUSTER HSA-MIR-1/133A IN GALLBLADDER CANCER (2012) Fuente: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (INICIO N5/2012) | Rol: INV. RESPONSABLE
- CHARACTERIZATION OF CONNECTIVE TISSUE GROWTH FACTOR CTGF IN GALLBLADDER CANCER CELL LINES (2009) Fuente: UNIVERSIDAD DE LA FRONTERA (DIUFRO DI09-0082) | Rol: INV. RESPONSABLE
- EVALUATION OF IMMUNOHISTOCHEMICAL EXPRESSION OF PROTEINS ASSOCIATED TO DNA REPLICATION COMPLEXS AS PROGNOSTIC MARKERS IN GASTRIC CANCER (2007) Fuente: UNIVERSIDAD DE LA FRONTERA (DIUFRO DI07-0111) | Rol: INV. RESPONSABLE
- ESTABLISHMENT AND EXPLOITATION OF A EUROPEAN-LATIN AMERICAN RESEARCH CONSORTIUM TOWARDS ERADICATION OF PREVENTABLE GALLBLADDER CANCER (EULAT ERADICATE GBC) (2019) Fuente: Horizon 2020 Framework Programme(European Commission;LU) | Rol:
- EUROPEAN-LATIN AMERICAN NETWORK FOR THE ASSESSMENT OF BIOMARKERS TO PREDICT AND DIAGNOSE HEPATOBILIARY MALIGNANCIES AND CHARACTERIZATION OF RISK FACTORS FOR CANCER DEVELOPMENT (ESCALON) (2019) Fuente: Horizon 2020 Framework Programme(European Commission;LU) | Rol:
Tus publicaciones
- ENVIRONMENTAL AND LIFESTYLE RISK FACTORS IN THE CARCINOGENESIS OF GALLBLADDER CANCER Autores: Pablo Pérez-Moreno;Ismael Riquelme;Patricia Garcia;Priscilla Brebi;Roa JC; Año: 2022 Link: https://doi.org/10.3390/jpm12020234
- VALIDATION OF AN NGS PANEL DESIGNED FOR DETECTION OF ACTIONABLE MUTATIONS IN TUMORS COMMON IN LATIN AMERICA Autores: Patricia Garcia; Año: 2021 Link: https://doi.org/10.3390/jpm11090899
- CURRENT AND NEW BIOMARKERS FOR EARLY DETECTION PROGNOSTIC STRATIFICATION AND MANAGEMENT OF GALLBLADDER CANCER PATIENTS Año: 2020 Link: https://doi.org/10.3390/cancers12123670
- FUNCTIONAL AND GENOMIC CHARACTERIZATION OF THREE NOVEL CELL LINES DERIVED FROM A METASTATIC GALLBLADDER CANCER TUMOR Año: 2020 Link: https://doi.org/10.1186/s40659-020-00282-7
- INTEGRATED GENOMIC ANALYSIS REVEALS MUTATED ELF3 AS A POTENTIAL GALLBLADDER CANCER VACCINE CANDIDATE Año: 2020 Link: https://doi.org/10.1038/s41467-020-17880-4
- LANDSCAPE OF GENOME-WIDE DNA METHYLATION OF COLORECTAL CANCER METASTASIS Año: 2020 Link: https://doi.org/10.3390/cancers12092710
- EVALUATION OF THE CHEMOPREVENTIVE POTENTIALS OF EZETIMIBE AND ASPIRIN IN A NOVEL MOUSE MODEL OF GALLBLADDER PRENEOPLASIA Año: 2020 Link: https://doi.org/10.1002/1878-0261.12766
- HIPPO-YAP1 IS A PROGNOSIS MARKER AND POTENTIALLY TARGETABLE PATHWAY IN ADVANCED GALLBLADDER CANCER Año: 2020 Link: https://doi.org/10.3390/cancers12040778
- A NOVEL GEMCITABINE-RESISTANT GALLBLADDER CANCER MODEL PROVIDES INSIGHTS INTO MOLECULAR CHANGES OCCURRING DURING ACQUIRED RESISTANCE Autores: Luis Vergara-Gómez;Carolina Bizama;Jun Zhong;Kurt Buchegger;Felipe Suárez;Lorena Rosa;Carmen Ili;Helga Weber;Javiera Obreque;Karena Espinoza;Gabriela Repetto;Roa JC;Pamela Leal;Patricia Garcia; Año: 2023 Link: https://doi.org/10.3390/ijms24087238
- GALLBLADDER CANCER Autores: Roa JC;Patricia García;Vinay K. Kapoor;Shishir K. Maithel;Milind Javle;Jill Koshiol; Año: 2022 Link: https://doi.org/10.1038/s41572-022-00398-y
Palabras clave relacionadas
Sobre Pontificia Universidad Católica de Chile
Pontificia Universidad Católica de Chile strives to provide its students with an educational experience that motivates both personal growth and the development of an inquisitive and critical mind. One of our objectives is to educate persons who are committed to the construction of a more just and prosperous society.
Our University is an important national center for research in social sciences, natural sciences, health, economics, agriculture, philosophy, theology, arts and literature.

Enviar una solicitud de información
a Pontificia Universidad Católica de Chile
Al hacer clic en «Enviar mensaje» estás registrándote en Innoget.com y aceptando nuestros Condiciones de uso y Política de privacidad
Acerca de las ofertas tecnológicas
Las Ofertas Tecnológicas en LinkIA se publican directamente
y es gestionada por sus miembros, así como la evaluación de las solicitudes de información. LinkIA es la red científica y de innovación abierta de confianza destinada a conectar directamente en línea las necesidades de la industria con los profesionales.
Ayuda
¿Necesita ayuda para solicitar información adicional o tiene alguna pregunta sobre esta Oferta Tecnológica?
Contactar con soporte de LinkIA